This text is a result of machine translation.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
ZD Medtech Raised Over CNY 100 Mn in Series B
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Medical Technology Company MacroLux Nets Nearly CNY 100 Mn in Series A
ForLong Biotech Nets Over CNY 100 Mn in Series A
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Kanghong’s Conbercept Receives Marketing Authorization in Guyana
Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).
Updated 3 hours ago
Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand
Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.
Aug 13, 2026 02:38 PM
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn
Levostar Completes Pre-A Financing Round to Further Invest in CGT
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
Alphamab Licenses Cancer Drug to Pathos AI in Deal Worth More Than US$2.2 Billion
Alphamab Oncology (康宁杰瑞生物制药) has licensed the overseas rights to its experimental cancer drug JSKN016 to US-based Pathos AI in a deal potentially worth more than US$2.2 billion, marking another major overseas licensing agreement for China’s rapidly expanding innovative-drug sector.
Aug 06, 2026 05:41 PM
Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar
Mabwell (Shanghai) Bioscience Co., Ltd.(迈威(上海)生物科技股份有限公司)has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.
Jul 31, 2026 03:00 PM
BlissBio Nets Over CNY 100 Mn in Series B+
Medical Equipment Company PowerSite Nets Over CNY 100 Mn in Series B
Equipment Company Keyto Nets Over CNY 100 Mn in Series C
IVD Company Bioantibody Nets Over CNY 100 Mn in Series A
Beyond Capital: Why Europe Needs Industrial Partners, Not Just Investors
Aug 04, 2026 11:21 AM
A Small Aircraft, a Bigger Bet: How China's Worthy Aero Plans to Scale Up
Jul 31, 2026 02:44 PM